Pliant Therapeutics (PLRX) AI Stock Analysis

520 Followers

Pliant Therapeutics

(NASDAQ:PLRX)

Select Model

Rating:42Neutral

Price Target:$0.71▼(-4.05% Downside)

Action:reiterated

Date:11/13/26

The score is pressured primarily by weak fundamentals (no TTM revenue, ongoing losses, and negative free cash flow despite improvement) and bearish technicals (below major moving averages with negative MACD). Valuation provides limited support because losses make the P/E not meaningful and no dividend yield is available.

Positive Factors

Targeted pipelineA focused small-molecule platform aimed at validated fibrosis biology gives Pliant a coherent development strategy rather than a scattered pipeline. Progress in IPF and related indications could create multiple opportunities from shared scientific expertise, supporting longer-term business development potential.

Negative Factors

No current revenueThe absence of current revenue means Pliant remains dependent on financing or other sources of capital to support operations and clinical development. Without commercial sales, the company has limited internal funding capacity and continued uncertainty around when its pipeline can generate durable cash inflows.

Pliant Therapeutics (PLRX) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $45.82M
Dividend Yield: ―
Average Volume (3M): 385.63K
Price to Earnings (P/E): -0.5
Beta (1Y): 1.29
Revenue Growth: ―
EPS Growth: 55.84%
Country: US
Employees: 49
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Pliant Therapeutics Business Overview & Revenue Model

Company Description

Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship inve...

Pliant Therapeutics Financial Statement Overview

Summary

Financial profile remains weak with no TTM revenue, sizable net losses (~$90M TTM), and still-negative operating/free cash flow (~-$67M TTM). Positives include meaningful improvement versus prior periods (losses and cash burn have narrowed) and manageable leverage (TTM debt-to-equity ~0.20), but the sharply declining equity base and deeply negative ROE (~-53%) point to ongoing funding and sustainability risk.

Income Statement

12Very Negative

Balance Sheet

44Neutral

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	0	0	1.58M	9.69M	7.57M
Gross Profit	-264.00K	-1.70M	0	1.58M	9.69M	7.57M
EBITDA	-90.72M	-145.09M	-205.16M	-158.23M	-120.71M	-95.73M
Net Income	-90.36M	-149.34M	-210.30M	-161.34M	-123.32M	-97.26M
Balance Sheet
Total Assets	169.88M	225.23M	396.95M	512.15M	350.61M	221.22M
Cash, Cash Equivalents and Short-Term Investments	141.08M	190.94M	355.72M	494.25M	331.19M	200.60M
Total Debt	27.78M	29.11M	60.19M	11.37M	15.81M	7.19M
Total Liabilities	43.24M	44.02M	92.87M	38.58M	37.27M	22.16M
Stockholders Equity	126.63M	181.21M	304.08M	473.58M	313.34M	199.06M
Cash Flow
Free Cash Flow	-66.79M	-128.71M	-159.35M	-117.28M	-96.39M	-77.40M
Operating Cash Flow	-66.79M	-128.34M	-155.50M	-116.36M	-94.63M	-75.44M
Investing Cash Flow	31.75M	134.29M	140.34M	-127.01M	-150.20M	73.70M
Financing Cash Flow	-32.13M	-31.70M	23.12M	274.40M	226.85M	2.53M

Pliant Therapeutics Technical Analysis

Technical Analysis SentimentNegative

Last Price0.74

Price Trends

50DMA0.98Negative

100DMA1.05Negative

200DMA1.14Negative

Market Momentum

MACD-0.06Positive

RSI24.60Positive

STOCH9.75Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLRX, the sentiment is Negative. The current price of 0.74 is below the 20-day moving average (MA) of 0.85, below the 50-day MA of 0.98, and below the 200-day MA of 1.14, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 24.60 is Positive, neither overbought nor oversold. The STOCH value of 9.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PLRX.

Pliant Therapeutics Risk Analysis

Pliant Therapeutics disclosed 82 risk factors in its most recent earnings report. Pliant Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.We are a "smaller reporting company," and the scaled disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.Q4, 2025

2.Our failure to meet Nasdaq's continued listing requirements could result in a delisting of our common stock.Q4, 2025

3.Shareholder activism could cause us to incur significant expense, disrupt our business, result in a proxy contest or litigation and impact our stock price.Q4, 2025

Pliant Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

PLRX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GOSS	47Neutral	$71.50M	-0.31	99.85%	―	78.03%	34.96%
GUTS	45Neutral	$11.69M	-0.06	-1625.88%	―	-100.00%	46.66%
RNTX	43Neutral	$52.28M	-0.30	-234.45%	―	―	36.23%
PLRX	42Neutral	$48.15M	-0.49	-53.22%	―	―	55.84%
ALGS	38Underperform	$15.22M	-0.31	-206.30%	―	1171.58%	49.20%
ATYR	33Underperform	$16.60M	-0.29	-102.46%	―	-100.00%	34.89%

* Healthcare Sector Average

Performance Comparison

PLRX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
PLRX	Pliant Therapeutics, Inc.	0.74	-0.91	-55.15%
ATYR	Atyr Pharma Inc.	6.21	-21.00	-77.18%
RNTX	Rein Therapeutics, Inc	0.56	-0.66	-54.10%
GOSS	Gossamer Bio	11.24	-227.96	-95.30%
ALGS	Aligos Therapeutics, Inc.	1.98	-5.04	-71.79%
GUTS	Fractyl Health, Inc.	0.81	-16.35	-95.27%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026

Pliant Therapeutics AI Stock Analysis